Suppr超能文献

原发性肝癌切除术后复发性肝癌患者的生存:治疗方式的比较效果。

Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities.

机构信息

Department of Surgery, National Taiwan University, Taipei, Taiwan.

出版信息

Surgery. 2012 May;151(5):700-9. doi: 10.1016/j.surg.2011.12.015. Epub 2012 Jan 28.

Abstract

BACKGROUND

Insufficient data are available on the survival of recurrent hepatocellular carcinoma after primary hepatectomy in patients receiving different treatments. We evaluated retrospectively the effects of treatment modalities on long-term survival.

METHODS

Between 2001 and 2007, 435 posthepatectomy hepatocellular carcinoma patients who developed recurrence were grouped by treatment modality into re-resection, radiofrequency ablation, transarterial chemoembolization, and supportive treatment groups. Treatment strategies for both primary hepatocellular carcinoma and its recurrence were selected using the same criteria. Postrecurrence survival was estimated using the Kaplan-Meier method and compared using the Cox proportional hazard model with adjusted independent prognostic factors. Survival rates after primary resection without recurrence were also compared.

RESULTS

In re-resection, radiofrequency ablation, transarterial chemoembolization, and supportive treatment groups, the 2-year postrecurrence survival rates were 90%, 96%, 75%, and 20%, respectively, and the 5-year survival rates were 72%, 83%, 56%, and 0%, respectively. The adjusted hazard of death was less for the re-resection and radiofrequency ablation groups than for the transarterial chemoembolization group, and the adjusted hazard ratios for the re-resection and radiofrequency ablation groups were 0.45 (95% confidence interval, 0.20-0.98) and 0.25 (0.08-0.81), respectively. The adjusted hazard ratio (95% confidence interval) of death for the radiofrequency ablation group compared to the re-resection group was 0.64 (0.19-2.19). Survival in the single resection group did not differ from that in the re-resection and radiofrequency ablation groups.

CONCLUSION

Postrecurrence survival in the re-resection and radiofrequency ablation groups was significantly better than that in the transarterial chemoembolization group and similar to that of patients in the primary resection without recurrence group.

摘要

背景

对于接受不同治疗的原发性肝切除术后复发性肝细胞癌患者,目前关于其生存的相关数据有限。本研究旨在评估治疗方式对长期生存的影响。

方法

本研究回顾性分析了 2001 年至 2007 年间 435 例接受肝切除术的复发性肝细胞癌患者的临床资料,根据治疗方式将其分为再次手术切除组、射频消融组、肝动脉化疗栓塞(TACE)组和支持治疗组。原发性肝细胞癌和复发性肝癌的治疗策略均采用相同的标准选择。采用 Kaplan-Meier 法估计无复发生存率,并采用 Cox 比例风险模型比较调整后的独立预后因素。还比较了无复发生存的原发性肝切除术后的生存率。

结果

在再次手术切除组、射频消融组、TACE 组和支持治疗组中,2 年复发后生存率分别为 90%、96%、75%和 20%,5 年生存率分别为 72%、83%、56%和 0%。与 TACE 组相比,再次手术切除组和射频消融组死亡的调整风险较低,调整后的危险比分别为 0.45(95%置信区间,0.20-0.98)和 0.25(0.08-0.81)。与再次手术切除组相比,射频消融组死亡的调整风险比为 0.64(95%置信区间,0.19-2.19)。单切除组的生存与再次手术切除组和射频消融组无差异。

结论

再次手术切除组和射频消融组的复发后生存明显优于 TACE 组,与无复发的原发性肝切除术后患者相似。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验